




Searching News Database: electroporation
HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 8 Jul 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
HSMN NewsFeed - 7 May 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
HSMN NewsFeed - 14 Nov 2018
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
HSMN NewsFeed - 4 Aug 2016
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
HSMN NewsFeed - 1 Apr 2014
Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
HSMN NewsFeed - 12 Jul 2010
AngioDynamics Expands Power-Injectable Port Portfolio with the Smart Port(R) CT Low-Profile and Mini Models
AngioDynamics Expands Power-Injectable Port Portfolio with the Smart Port(R) CT Low-Profile and Mini Models
HSMN NewsFeed - 20 May 2010
AngioDynamics Appoints Lynda Wallace Senior Vice President of Business Development
AngioDynamics Appoints Lynda Wallace Senior Vice President of Business Development
HSMN NewsFeed - 17 May 2010
AngioDynamics Launches First Product in Morpheus(R) Smart PICC Series, a Triple Lumen Version for CT Imaging
AngioDynamics Launches First Product in Morpheus(R) Smart PICC Series, a Triple Lumen Version for CT Imaging
HSMN NewsFeed - 10 May 2010
AngioDynamics Launches Improved Centros(R) Self-Centering Hemodialysis Catheter
AngioDynamics Launches Improved Centros(R) Self-Centering Hemodialysis Catheter
HSMN NewsFeed - 30 Dec 2009
AngioDynamics Launches Micro-Introducer Kits with a New Stiffened Introducer Option
AngioDynamics Launches Micro-Introducer Kits with a New Stiffened Introducer Option
HSMN NewsFeed - 27 Oct 2009
AngioDynamics Appoints Stephen McGill as Senior Vice President and General Manager, International
AngioDynamics Appoints Stephen McGill as Senior Vice President and General Manager, International
HSMN NewsFeed - 9 Dec 2008
AngioDynamics Appoints Vice President, Regulatory, Quality and Clinical Affairs
AngioDynamics Appoints Vice President, Regulatory, Quality and Clinical Affairs
HSMN NewsFeed - 6 Nov 2008
AngioDynamics to Launch VenaCure EVLT(TM), New Brand for Varicose Vein Treatment
AngioDynamics to Launch VenaCure EVLT(TM), New Brand for Varicose Vein Treatment
HSMN NewsFeed - 24 Apr 2008
First Human Use Demonstrates Effectiveness of Irreversible Electroporation Treatment
First Human Use Demonstrates Effectiveness of Irreversible Electroporation Treatment
HSMN NewsFeed - 21 Aug 2007
Inovio Biomedical Appoints Dr. Michael Fons as Vice President, Corporate Development
Inovio Biomedical Appoints Dr. Michael Fons as Vice President, Corporate Development
HSMN NewsFeed - 5 Jun 2007
Inovio Biomedical Stops Enrollment of Phase III Clinical Trials for Head & Neck Cancer
Inovio Biomedical Stops Enrollment of Phase III Clinical Trials for Head & Neck Cancer
HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
HSMN NewsFeed - 27 Nov 2006
AngioDynamics Announces FDA Clearance for Irreversible Electroporation Technology
AngioDynamics Announces FDA Clearance for Irreversible Electroporation Technology
HSMN NewsFeed - 14 Nov 2006
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
HSMN NewsFeed - 7 Nov 2006
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines
HSMN NewsFeed - 17 Oct 2006
AngioDynamics to Acquire Oncobionic and Its Revolutionary New Cancer Therapy
AngioDynamics to Acquire Oncobionic and Its Revolutionary New Cancer Therapy
HSMN NewsFeed - 17 Oct 2006
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
Inovio Biomedical Acquires Rights to DNA Vaccine Licenses and Intellectual Property from Valentis
Additional items found! 29

Members Archive contains
29 additional stories matching:
electroporation
(Password required)
electroporation
(Password required)